These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33335397)

  • 1. The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms.
    Sugawara N; Yasui-Furukori N; Tsuji T; Hayashi S; Ajisawa Y; Ochiai T; Imagawa H; Shimoda K
    Neuropsychiatr Dis Treat; 2020; 16():3063-3070. PubMed ID: 33335397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy.
    Kuga A; Otsubo T; Tsuji T; Hayashi S; Imagawa H; Fujikoshi S; Escobar R
    Neuropsychiatr Dis Treat; 2019; 15():809-817. PubMed ID: 31040680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life.
    Kuga A; Tsuji T; Hayashi S; Fujikoshi S; Tokuoka H; Yoshikawa A; Escobar R; Tanaka K; Azekawa T
    Neuropsychiatr Dis Treat; 2017; 13():2115-2124. PubMed ID: 28831260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis.
    Kuga A; Tsuji T; Hayashi S; Matsubara M; Fujikoshi S; Tokuoka H; Yoshikawa A; Escobar R; Tanaka K; Azekawa T
    Neuropsychiatr Dis Treat; 2017; 13():2105-2114. PubMed ID: 28831259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study.
    Harada E; Satoi Y; Kuga A; Tokuoka H; Kikuchi T; Watanabe K; Alev L; Mimura M
    Neuropsychiatr Dis Treat; 2017; 13():2437-2445. PubMed ID: 29033569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
    Novick D; Montgomery W; Haro JM; Moneta MV; Zhu G; Yue L; Hong J; Dueñas H; Brugnoli R
    Neuropsychiatr Dis Treat; 2016; 12():383-92. PubMed ID: 26966361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major depressive disorder severity and the frequency of painful physical symptoms: a pooled analysis of observational studies.
    Brnabic A; Lin C; Monkul ES; Dueñas H; Raskin J
    Curr Med Res Opin; 2012 Dec; 28(12):1891-7. PubMed ID: 23145858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression.
    Harada E; Satoi Y; Kikuchi T; Watanabe K; Alev L; Mimura M
    Neuropsychiatr Dis Treat; 2016; 12():1599-607. PubMed ID: 27418827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
    Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
    Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of antidepressants in the treatment of major depressive disorder in Latin America.
    Dueñas HJ; Dwight T; McBride ME; Brnabic AJ; Semper LA; Holmgren D; Miranda-Scippa AM; Rincón HG; Aguilera H; Vargas A
    Int J Psychiatry Clin Pract; 2007; 11(2):129-39. PubMed ID: 24937558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials.
    Wise TN; Meyers AL; Desaiah D; Mallinckrodt CH; Robinson MJ; Kajdasz DK
    Prim Care Companion J Clin Psychiatry; 2008; 10(4):270-5. PubMed ID: 18787676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors impacting the efficacy of venlafaxine extended release 75-225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan.
    Watanabe Y; Asami Y; Hirano Y; Kuribayashi K; Itamura R; Imaeda T
    Neuropsychiatr Dis Treat; 2018; 14():1261-1272. PubMed ID: 29844674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.
    Barros BR; Schacht A; Happich M; Televantou F; Berggren L; Walker DJ; Dueñas HJ
    Prim Care Companion CNS Disord; 2014; 16(5):. PubMed ID: 25667808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
    Fava M; Mallinckrodt CH; Detke MJ; Watkin JG; Wohlreich MM
    J Clin Psychiatry; 2004 Apr; 65(4):521-30. PubMed ID: 15119915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study.
    Novick D; Hong J; Montgomery W; Dueñas H; Gado M; Haro JM
    Neuropsychiatr Dis Treat; 2015; 11():197-205. PubMed ID: 25653529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East.
    Hong J; Novick D; Moneta MV; El-Shafei A; Dueñas H; Haro JM
    Clin Pract Epidemiol Ment Health; 2017; 13():145-155. PubMed ID: 29238391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.